Hepatology

Frailty has emerged as a therapeutic target in advanced chronic liver disease management, with non-pharmacological interventions showing promise.

Lifestyle modifications, particularly dietary changes, have shown potential in reversing MASLD and steatohepatitis.

A recent clinical trial investigated combining time-restricted feeding and flaxseed for MASLD treatment.

Among serum biomarkers, the FIB-4 and APRI scores are widely recognised for assessing advanced fibrosis and cirrhosis.

This study examined the efficacy and safety of pemafibrate in 360 patients with MASLD and hypertriglyceridaemia.

The study involved 419 patients, aged 18–75, with noncirrhotic PSC, who were randomly assigned to receive either cilofexor or a placebo over 96 weeks.

A new study reveals that AI can identify early-stage metabolic-associated steatotic liver disease using electronic health records.

This study assessed neutrophil extracellular traps and DNase activity in patients with chronic hepatitis B-related decompensated cirrhosis to determine their relationship with PVT.